TY - JOUR
T1 - Type 2 Diabetes Mellitus and Heart Failure, A Scientific Statement From the American Heart Association and Heart Failure Society of America
AU - Heart Failure Society of America
AU - American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology
AU - Council on Cardiovascular and Stroke Nursing
AU - Dunlay, Shannon M.
AU - Givertz, Michael M.
AU - Aguilar, D.
AU - Allen, Larry A.
AU - Chan, Michael
AU - Desai, Akshay S.
AU - Deswal, A.
AU - Dickson, Victoria Vaughan
AU - Kosiborod, Mikhail N.
AU - Lekavich, Carolyn L.
AU - McCoy, Rozalina G.
AU - Mentz, Robert J.
AU - PiÑa, Ileana L.
N1 - Funding Information:
Writing Group Disclosures Writing Group Member Employment Research Grant Other Research Support Speakers’ Bureau/Honoraria Expert Witness Ownership Interest Consultant/Advisory Board Other Shannon M. Dunlay Mayo Clinic, Rochester, MN None None None None None None None Michael M. Givertz Brigham and Women's Hospital None None None None None None None David Aguilar University of Texas Health Science Center None None None None None None None Larry A. Allen University of Colorado School of Medicine AHA † ; NIH, NHLBI † ; PCORI † None None None None ACI Clinical * ; Boston Scientific * ; Cytokinetics/ Amgen * ; Duke Clinical Research Institute * ; Janssen * None Michael Chan University of Alberta, Canada Novartis Company (local hospital PI for a clinical research study) * ; Merck Company (local hospital PI for a clinical research study) * None Novartis * ; Servier * None None Novartis * ; Servier * None Akshay S. Desai Brigham and Women's Hospital Novartis (research grant to Brigham and Women's Hospital) † None None None None Abbott † ; Astra Zeneca † ; Biofourmis * ; Boehringer Ingelheim * ; DalCor Pharma † ; Novartis * ; Regeneron † ; Relypsa * ; Signature Medical * None Anita Deswal Michael E. DeBakey VA Medical Center & Baylor College of Medicine VA Medical Center None None None None None None None Victoria Vaughan Dickson New York University College of Nursing None None None None None None None Mikhail N. Kosiborod Saint Luke's Mid America Heart Institute AstraZeneca (research grant, other research support) † ; Boehringer Ingelheim (research grant) † None None None None Amarin * ; Amgen † ; Applied Therapeutics * ; AstraZeneca † ; Bayer † ; Boehringer Ingelheim † ; Eisai † ; Glytec * ; GlaxoSmithKline * ; Intarcia * ; Janssen † ; Merck (Diabetes) † ; Novartis * ; Novo Nordisk † ; Sanofi † None Carolyn L. Lekavich Duke Clinical Research Institute, Duke University School of Medicine None None None None None None None Rozalina G. McCoy Mayo Clinic Rochester, MN NIH (K23DK114497) * None None None None None None Robert J. Mentz Duke University Medical Center Akros † ; Amgen † ; AstraZeneca † ; Bayer † ; GlaxoSmithKline † ; Luitpold/American Report † ; Medtronic † ; Merck † ; Novartis † (all are research support to institution); NIH (U01HL125511-01A1, U10HL110312, R01AG045551-01A1) † None None None None Abbott * ; Amgen * ; AstraZeneca * ; Bayer * ; BI * ; Merck * ; Novartis † None Ileana L. Piña Montefiore Medical Center None None None None None None None
Funding Information:
Reviewer Disclosures Reviewer Employment Research Grant Other Research Support Speakers’ Bureau/Honoraria Expert Witness Ownership Interest Consultant/Advisory Board Other Olakunle O. Akinboboye Laurelton Heart Specialists None None None None None None None Charlotte Andersson Herlev Gentofte Hospital (Denmark) None None None None None None None Prakash Deedwania UCSF None None None None None None None Lynne W. Stevenson Vanderbilt University None None None None None None None
Publisher Copyright:
© 2019 Elsevier Inc.
PY - 2019/8
Y1 - 2019/8
N2 - Type 2 diabetes mellitus is a risk factor for incident heart failure and increases the risk of morbidity and mortality in patients with established disease. Secular trends in the prevalence of diabetes mellitus and heart failure forecast a growing burden of disease and underscore the need for effective therapeutic strategies. Recent clinical trials have demonstrated the shared pathophysiology between diabetes mellitus and heart failure, the synergistic effect of managing both conditions, and the potential for diabetes mellitus therapies to modulate the risk of heart failure outcomes. This scientific statement on diabetes mellitus and heart failure summarizes the epidemiology, pathophysiology, and impact of diabetes mellitus and its control on outcomes in heart failure; reviews the approach to pharmacological therapy and lifestyle modification in patients with diabetes mellitus and heart failure; highlights the value of multidisciplinary interventions to improve clinical outcomes in this population; and outlines priorities for future research.
AB - Type 2 diabetes mellitus is a risk factor for incident heart failure and increases the risk of morbidity and mortality in patients with established disease. Secular trends in the prevalence of diabetes mellitus and heart failure forecast a growing burden of disease and underscore the need for effective therapeutic strategies. Recent clinical trials have demonstrated the shared pathophysiology between diabetes mellitus and heart failure, the synergistic effect of managing both conditions, and the potential for diabetes mellitus therapies to modulate the risk of heart failure outcomes. This scientific statement on diabetes mellitus and heart failure summarizes the epidemiology, pathophysiology, and impact of diabetes mellitus and its control on outcomes in heart failure; reviews the approach to pharmacological therapy and lifestyle modification in patients with diabetes mellitus and heart failure; highlights the value of multidisciplinary interventions to improve clinical outcomes in this population; and outlines priorities for future research.
KW - AHA Scientific Statement
KW - Diabetes mellitus, type 2
KW - Drug therapy
KW - Heart failure
KW - Lifestyle
KW - Risk factors
UR - http://www.scopus.com/inward/record.url?scp=85070222492&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85070222492&partnerID=8YFLogxK
U2 - 10.1016/j.cardfail.2019.05.007
DO - 10.1016/j.cardfail.2019.05.007
M3 - Article
C2 - 31167558
AN - SCOPUS:85070222492
SN - 1071-9164
VL - 25
SP - 584
EP - 619
JO - Journal of Cardiac Failure
JF - Journal of Cardiac Failure
IS - 8
ER -